Original Article

15-LOX Inhibitors: Biochemical Evaluation of Flurbiprofen and its Derivatives

Saghir Abbas, Sumera Zaib, Saqib Ali, Jamshed Iqbal

ABSTRACT

Objective: The synthesis, characterization, 15-LOX inhibition and molecular docking studies of a commercially available NSAID, flurbiprofen and its derivatives.

Study Design: Experimental study.

Place and Duration of Study: The study was carried out at Quaid-i-Azam University and Centre for Advanced Drug Research COMSATS University Islamabad, Abottabad Campus from March 2019 to February 2020.

Materials and Methods: The structural elucidation of the compounds (2-5) was carried out using infrared, $^1$H and $^{13}$C NMR spectroscopic studies. The structure of 4-amino-5-[1-(2-fluorobiphenyl-4-yl)-ethyl]-4H-1,2,4-triazole-3-thione (5) was also verified by single crystal X-ray diffraction (XRD) studies.

Results: The most potent inhibitor for 15-LOX (2) has an IC₅₀ value of 0.18 ± 0.01 µM. Molecular docking results of 1, 2, 3 and cognate ligand inside the active site of 15-LOX (PDB ID: 1IK3) revealed significant correlation.

Conclusion: This work represents cost-effective, reproducible and facile conversion of an aromatic monocarboxylic acid into potent derivatives. The molecules 2-(2-fluorobiphenyl-4-yl) propanoic acid (1) and its derivatives (2-5) possess 15-LOX inhibition and can be a prospective therapeutic target for chronic obstructive pulmonary disease.

Key Words: Hydrazide, Lipoxygenase Inhibition, Molecular Docking, X-Ray Diffraction, 1,2,4-Triazole-3-Thione.

How to cite this: Abbas S, Zaib S, Ali S, Iqbal J. 15-LOX Inhibitors: Biochemical Evaluation of Flurbiprofen and its Derivatives. Life and Science. 2020; 1(3): 92-97. doi: http://doi.org/10.37185/LnS.1.1.107

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Lipoxygenase (LOX) join a non-heme family of iron containing dioxygenase enzymes which introduce oxygen into linoleic acid and arachidonic acid through regio- and stereospecific pathway and convert these fatty acids into hydroperoxy fatty acids.$^{1,3}$ These hydroperoxy fatty acids are converted into leukotrienes and lipoxins which are important regulators for many diseases. The LOX family contains 5-LOX, 9-LOX, 12-LOX, and 15-LOX isozymes, which oxidize the main fatty acid arachidonic acid at their respective 5, 9, 12 and 15 positions.$^4$ These isozymes also perform crucial part in the development of the pathophysiology of many diseases in humans, thus they could be a potential targets for therapeutic regime modulation.$^5$ Among them 15-LOX is the most influential target, which is involved in pathology of certain carcinomas, chronic obstructive pulmonary disease (COPD) and atherosclerosis.$^6,12$

15-LOX has this name because it catalyses addition of oxygen at position 15 of arachidonic acid. The oxidation of linoleic acid with LOX isozymes can produce pro-thrombotic$^{13}$ pro-inflammatory$^{14}$ and leukotrienes molecules.$^{15}$ Leukotrienes are highly involved in multiple pathological conditions, i.e., asthma, pleural effusion, pneumonia, tuberculosis, pulmonary embolism, congestive heart failure and lung cancer etc.$^{16-18}$ Thus, inhibition of lipoxygenases prevents development of leukotrienes and related pro-inflammatory metabolite production. A significant number of lipoxygenase inhibitors have reached log P values of 5 and above, but the

---

1 Department of Biological Sciences
National University of Medical Sciences, Rawalpindi
2 Centre for Advanced Drug Research
COMSATS University
Abbottabad Campus, Abbottabad
3 Department of Chemistry
Quaid-I-Azam University, Islamabad

Correspondence:
Prof Dr. Jamshed Iqbal
Centre for Advanced Drug Research
COMSATS University
Abbottabad Campus, Abbottabad
E-mail: drjamshed@cuiatd.edu.pk

Funding Source: HEC; Conflict of Interest: NIL
Received: Mar 24, 2020; Revised: Apr 21, 2020
Accepted: Jun 08, 2020
determined lipid ligand performances are generally low. From this viewpoint, it is extremely important to discover new analogues for innovative substitution patterns for formerly known lipoxygenase binding core structures. This mechanism can introduce inhibitors with improved physicochemical characteristics.

Heterocyclic triazole compounds have tremendous applications as synthetic intermediates in medicines as antimicrobial, antibacterial, and antitrypanosomal agents. Triazole is a n-conjugated system carrying sp2-amine and sp2-imine-type nitrogen atoms with multiple coordination modes rendering them superior to imidazole and pyrazoles. Triazoles are generally classified as bases because they happen in the protonated form as azolium cation, however they can also be deprotonated to form azolate (or azolide) anion. Triazole bases can be synthesized by the modification of carboxylic functional group of nonsteroidal anti-inflammatory drugs (NSAIDs) for potential anti-viral and in vitro cytotoxic applications.

In the current study, we present the synthesis, characterization, 15-LOX inhibition and molecular docking studies of a commercially available (NSAID) flurbiprofen and its derivatives.

Materials and Methods

2-(2-fluorobiphenyl-4-yl) propanoic acid (1) and the solvents used were bought from E. Merck (Germany). The solvents were dried before use employing the standard procedures. The biological test materials were obtained from as mentioned previously. A Gallenkamp melting point apparatus was utilized to determine melting points. Infrared measurements were recorded on a Bruker Tensor II spectrophotometer. 1H and 13C-NMR spectra were determined on a Bruker 300 MHz NMR spectrometer using deuterated dimethyl sulfoxide. Single crystal XRD studies were done using a Bruker Kappa APEX-II CCD diffractometer (Mo X-ray source). SHELXL-97 was used to obtain final refinements of the crystal structure.

Chemical synthesis: The compounds (2-5) were synthesized adopting the same synthesis route reported in our previous work. All the derivatives were obtained in good yield (70-80%).

Procedure for the synthesis of 2 and 3: A condensation reaction was carried out in order to synthesize ethyl-2-(2-fluorobiphenyl-4-yl) propanoate (2). To an ethanolic solution of 2-(2-fluorobiphenyl-4-yl) propanoic acid (2 mmol) few drops of conc. H2SO4 catalyst was added and the resulting solution was kept at reflux conditions for 6 hours. Formation of the product was checked using pre-coated silica gel TLC plates applying chloroform: methanol (8:2) eluent. The reaction mixture was rotary evaporated to extract ester from alcohol and was purified by solvent extraction methodology using a NaHCO3 solution. The obtained ester was coverted into 2-(2-fluorobiphenyl-4-yl) propane hydrazide (3) by dissolving compound 2 and hydrazine hydrate (1:2) in C6H6OH (50 mL) and refluxing the reaction mixture for 8 hrs (scheme A). TLC plates were used to monitor the reaction progress employing petroleum ether: ethyl acetate (1:1) eluent. A pure yellow colour solid of hydrazide (3) was achieved by recrystallization from methanol.

Procedure for the synthesis of 4 and 5: To an iced-cooled alcoholic KOH (0.03 moles) solution, 2-(2-fluorobiphenyl-4-yl) propane hydrazide (0.015 moles) and carbon disulphide (0.025 mol) was added. The reaction progressed at reflux conditions and constant stirring for 12 hours. A solid potassium thiocarbamate (4) was obtained by rotary evaporation of solution. Potassium thiocarbamate was washed several times with ethanol, dried and employed further for the ring closure reaction leading towards synthesis of a triazole moiety (5). For the preparation of a triazole compound, hydrazine hydrate (0.02 mol) was added dropwise to an aqueous solution of 4. The resulting solution was kept at reflux conditions for 10 hours where a release of the hydrogen sulphide gas was observed during reaction turning the reaction mixture green. The reaction mixture was cooled and acidified using dilute HCl to produce the desired product (5). At this time, toluene: ethyl acetate: formic acid (5:4:1) eluent was employed for TLC monitoring of the reaction.

Scheme A: Synthesis of 4-amino-5-(1-(2-fluorobiphenyl-4-yl)-ethyl)-4H-1,2,4-triazole-3-thione (5).
**Physical measurements:** The physical measurements have been reported in our previous work.  

**Biological assays**

**15-Lipoxygenase inhibition assay:** Lipoxygenase inhibition studies were performed with slight modifications in previously reported spectrophotometric method. Briefly, 10 uL of 15-LOX (soybean source, 42.5 U) was mixed with 20 uL compound (0.1 mM in 1% DMSO) in 145 uL of KH2PO4 buffer (100 mM, pH 8.0). The reaction mixture was incubated at 25°C for 10 min and absorbance was measured at 234 nm using a microplate reader (FLUOstar Omega (BMG Labtech, Offenburg, Germany). The reaction started with the addition of 25 uL of linoleic acid as substrate, followed by incubation for 6 min and the change in absorbance was measured. Quercetin was used as a positive control. All the experiments were performed in triplicates. The compounds exhibiting >50% inhibition was subjected to further evaluation of IC50 values by non-linear regression analysis.

**Molecular docking:** To evaluate the binding mode of dual inhibitors within the active site of the enzyme, high-resolution crystal structure of 15-LOX (PDB ID: 1IK3, 2.0 Å resolution) was downloaded from the RCSB Protein Data Bank. To explore the binding mode of favourable inhibitors within the active site of enzyme different conformations of same ligands were studied. The enzyme structure was clarified for missing amino acids and bonds contacts. The receptors were prepared using MOE. Docking studies of selected inhibitors and cognate ligand was carried out using LeadIT software using default parameters. The ligands were kept flexible with fixed protein conformation, docking was carried out treating all the single bonds as rotatable. Different conformations were obtained after each run and the top ranked poses with minimum energies was selected for visualization using BIOVIA Discovery Studio.

**Results**

**Spectroscopic study:** The structural elucidation of 2-5 was carried out by IR, 1H and 13C NMR spectroscopy. The infrared spectrum showed a relatively strong absorption band at 3405 cm⁻¹ and 3388 cm⁻¹ for νNH, and at 3196 and 3188 cm⁻¹ for νNH group of hydrazide (3) and 1,2,4-triazole-thione (5) structure, respectively, confirming the formulation of products. The typical IR band at 1077 cm⁻¹ for C=S stretching proved the existence of a thione moiety in 5. The 1H and 13C NMR spectra for the flurbiprofen derivatives were obtained in deuterated solvents (2,3 in CDCl3; 5 in DMSO-d6). The chemical shift values assigned to protons and carbons harmonized well with the assessed molecular composition of 2-5. The 1H and 13C NMR spectra of 5 have been shown in Figure 1 and 2. The formation of 2-(2-fluorobiphenyl-4-yl) propanate (2) was inveterated due the absence of chemical shift value for the carboxylic proton and presence of a new peak at 4.21 ppm for -O-CH2 group in the 1H NMR spectrum. The 1H NMR spectrum exhibited a singlet at 8.20 ppm for NH proton of 3 present contiguous to the C=O group. Additionally, a broad singlet for two protons of NH group, at 3.60 ppm specified the preparation of 3. A downfield shift for NH proton at 13.65 ppm for the triazole moiety (5) matches well with the reported value.

The NH proton in 5 occurs as thione-thiol tautomeric arrangement. The thione form dominates in the structure which was confirmed by the absence of absorption frequency for a thiol (-SH) functional group in the infrared spectrum and it was also supported by single crystal XRD data (Figure 1). The 1H NMR presented a singlet at 5.50 for the NH group in 5. 13C NMR spectroscopic results indicate the vanishing of (C=O) peak of hydrazide (3) appeared at 173.4 ppm while the appearance of a new peak for (C=S) at 166.8 ppm for a thione functional group indicated the synthesis of a 1,2,4-triazole-3-thione moiety.

**Fig 1.** 1H NMR spectrum of 5

**X-ray diffraction studies:** XRD analysis data has been previously reported by our group. The crystallographic information is provided in Table 1.
while the hydrogen bond geometry in 5 is presented in Table 2. The molecular structure of 5 is given in Figure 3 while the symmetrical order and H-interaction pattern is presented in Figure 4 and 5. X-ray diffraction studies indicate that 5 crystallized out in a monoclinic crystal system with a space group P21/n. Two N-H...S interactions occur, one of them ends into an S (5) ring and other gives a dimer with R21 (10) ring (Figure 4).

**Table 1: The crystal refinements and structural parameters for 5**

| Compound Properties | 5       | 1535916 |
|---------------------|---------|---------|
| CCDC #              |         |         |
| Chemical formula    | C60 H15 F N4 S |
| Formula weight      | 314.38  |         |
| Crystal colour      | Colourless |
| Crystal description | Rod     |         |
| T / K               | 296(2)  |         |
| Wavelength / Å      | 0.71073 |         |
| Crystal system      | Monoclinic |
| Space group         | P21/n   |         |
| a / Å               | (6.1601(2)) |
| b / Å               | (13.7424(7)) |
| c / Å               | 18.1717(9) |
| α / °               | 90      |         |
| β / °               | 90      |         |
| γ / °               | 97.771(2) |
| V / Å³              | 1524.19(12) |
| Z                   | 4       |         |
| F(000)              | 656     |         |

**Table 2: Hydrogen -bond geometry (Å) in compound 5**

| D—H···A | D—H | H···A | D···A | D—H···A |
|---------|------|-------|-------|---------|
| O2—H2A—N2 | 0.82 | 1.93  | 2.650 (3) | 146 |
| N1—H1—O3  | 0.86 | 2.01  | 2.858 (3) | 170 |
| O4—H4A—N4 | 0.82 | 1.89  | 2.615 (3) | 147 |
| N3—H3A—O1  | 0.86 | 2.17  | 2.846 (3) | 135 |

Symmetry codes: (i) -x+1/2, y+1/2, z-1/2 (ii) -x+1/2, y-1/2, z-1/2

**Table 3: 15-Lipoxygenase inhibition results against flurbiprofen (1) and its derivatives**

| Codes | 15-LOX (IC50±SEM (µM)) |
|-------|--------------------------|
| 1     | 0.41 ± 0.06              |
| 2     | 0.18 ± 0.01              |
| 3     | 0.46 ± 0.03              |
| 4     | 1.18 ± 0.11              |
| 5     | 1.61 ± 0.14              |
| Quercetin | 15.8 ± 0.61           |

**15-Lipoxygenase inhibition assay:** 15-Lipoxygenase inhibition assay was performed on all the synthesized compounds (2-5) and their precursor (1) (Table 3). The ester derivative (2) of flurbiprofen showed promising results against 15-LOX enzyme with an IC50 value of 0.18±0.01 µM only depicting an 87-fold higher inhibition than the reference quercetin (positive control). Moreover, compounds 1 and 3 also exhibited very promising inhibition results against 15-LOX.
Molecular docking studies of 15-LOX: To anticipate the binding interactions of most potent inhibitors, molecular docking studies were done for selected compounds 1, 2 and 3 along with cognate ligand (Trans-12,13-epoxy)-9-hydroxy-10(E)-octadecenoic acid) in its respective binding site (PDB ID: 1IK3). The interactions of cognate ligand include hydrogen bonding with Arg726 and His513, while π-π interactions and π-σ interactions with Ile772, Leu277, Leu560, Ser510 and Ile857. However, 1 showed significant interactions with Tyr512, Leu376, Arg378 and Pro432 within the active pocket of 15-LOX. However, 2 exhibited several interactions like π-π and π-σ with amino acids Leu376, Pro432, Tyr512, Asn521, Arg378 and Asn375. Most notable interactions were demonstrated by 3 within the active pocket of 15-LOX (Figure 6).

**Discussion**

Herein, biologically important ester, hydrazide, thiocarbamate and 1,2,4-trizole-3-thione derivatives of flurbiprofen, (2-(2-fluorobiphenyl-4-yl) propanoic acid) have been synthesized and characterized. The infrared spectroscopic studies indicated that a thione tautomer of 5 is formed which was also confirmed by single crystal X-ray diffraction analysis. In addition to this, the formation of a thione moiety instead of a thiol functional group has been further confirmed by the appearance of a peak at 166.8 ppm for \{C=S\} in 13C NMR spectroscopy. Biological evaluation data shows that compound 2 is the most potent 15-LOX inhibitor with an IC50 value of 0.18 ± 0.01 μM. Molecular docking results show that 1, 2, 3 and cognate ligand inside the active site of 15-LOX (PDB ID: 1IK3) revealed significant correlation. It is found that 1, 2 and 3 along with cognate ligand in its respective binding site (PDB ID: 1IK3) demonstrated hydrogen bonding, π-π and π-σ interactions while 1 exhibited fascinating interactions with Tyr512, Leu376, Arg378 and Pro432 within the active pocket of 15-LOX. Besides, compound 3 demonstrated most significant interactions within the active pocket of 15-LOX, which revealed hydrogen bonding along with π-π and π-σ interactions.

**Conclusion**

This work represents cost-effective, reproducible, and facile conversion of an aromatic monocarboxylic acid into potent derivatives. This study showed that flurbiprofen (1) (non-selective LOX inhibitor) and its derivatives causes inhibition of LOX enzyme. This is referred as drug repurposing and polypharmacology that result in therapeutic synergism. Inhibition of lipooxygenase causes bronchodilation by reducing leukotrienes. In COPD, inhibition of the enzyme is
required to reduce pleural effusion and induce bronchodilation. Current study showed that the cognate ligand (Trans-12,13-epoxy)-9-hydroxy-10(E)-octadecenoic acid) bound through hydrogen bonding with Arg726 and His513, while it showed π-π interactions and π-σ interactions with Ile772, Leu277, Leu560, Ser510 and Ile857. 15-LOX inhibition results indicated that the most potent inhibitor (2) for 15-LOX has an IC₅₀ value of 0.18 ± 0.01 µM. It is concluded that 2-(2-fluorobiphenyl-4-yl) propanoic acid (1) and its derivatives (2-5) possess 15-LOX inhibition and can be a prospective therapeutic target for COPD and atherosclerosis.

Acknowledgements

J. I. is thankful to the Higher Education Commission of Pakistan for the financial support through Project No. Ph-V-MG-3/Peridot/R&D/HEC/2019.

REFERENCES

1. Li QQ, Li Q, Jia JN, Liu ZQ, Zhou HH, Mao XY. Neurochem. Int. 2018; 118: 34-41.
2. Eleftheriadis N, Neochoritis CG, Leus NGJ, van der Wouden PE, Domling A, Dekker FJ. J. Med. Chem. 2015; 58: 7850-62.
3. van der Vlag R, Guo H, Hapko U, Eleftheriadis N, Monjas L, Dekker FJ, et al. Eur. J. Med. Chem. 2019; 174: 45-55.
4. Kuhn H, Banthiya S, Van Leyen K. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2015; 1851: 308-30.
5. Brash AR, Lipoxygenases J. Biol. Chem. 1999; 274: 23679–82.
6. Solomon EI, Zhou J, Neese F, Pavel EG. Chem. Biol. 1997; 4: 795–808.
7. Brash AR. J. Biol. Chem. 1999; 274: 23679–82.
8. Kuhn H, Thiele BJ. FEBS Lett. 1999; 449: 7–11.
9. Wang MT, Honn KV, Nie D. Cancer Metastasis Rev. 2007; 26: 525–34.
10. Kuhn H, Walther W, Kuban RJ. Prostaglandins Other Lipid Mediat. 2002; 68: 263-90.
11. Poooryaghoobi N, Bakavoli M, Alimardani M, Bazzazan T, Sadeghian H. Iran. J. Basic Med. Sci. 2013; 16: 784–9.
12. Setty B, Werner M, Hannun Y, Stuart M. Blood. 1992; 80: 2565-73.
13. Sultana C, Shen Y, Rattan V, Kalra K. J. Cell. Physiol. 1996; 167: 477–87.
14. Abe M, Yoshimoto T, Zashti NY. 2004; 124: 415–25.
15. Volovitz B, Welliver RC, De Castro G, Krystofik DA, Ogra PL. Pediatr. Res. 1988; 24: 504–7.
16. Gentile DL, Fireman, Skoner DP. Ann. Allergy. Asthma Immunol. 2003; 91: 270–4.
17. Funk CD. Nat. Rev. Drug Discov. 2005; 4: 664–72.
18. Klein M, Krainz K, Redwan IN, Dinér P, Görtl M. Molecules. 2009; 14: 5124–43.
19. Bayrak H, Demirbas A, Demirbas N, Karaoglu SA. Eur. J. Med. Chem. 2009; 44: 4362–6.
20. El T, Ali S, Mohammed A, Kazak E. Eur. J. Chem. 2010; 1: 7–12.
21. Tehranchian S, Akbarzadeh T, Fazeli MR, Jamalifar H, Shafiee A. Bioorg. Med. Chem. Lett. 2005; 15: 1023–5.
22. Papadopoulou MV, Bloomer WD, Rosenzweig HS, Chatelain E, Kaiser M, Wilkinson SR, et al. J. Med. Chem. 2012; 55: 5554–65.
23. Küçükgüzel SG, Küçükgüzel I, Tatar E, Rollas S, Şahin F, Gülüce M, et al. J. Med. Chem. 2007; 42: 893–901.
24. Amir M, Kumar H, Javed SA, Bioorg. Med. Chem. Lett. 2007; 17: 4504–8.
25. Malterud KE, Rydland KM. J. Agric. Food Chem. 2000; 48: 5576-80.
26. Holmes RR, Schmid CG, Chandrasekhar V, Day R, Holmes JM. J. Am. Chem. Soc. 1987; 109: 1408–14.
27. Abbas S, Zaib S, Rahman S, Ali S, Hameed S, Tahir MN, et al. J. Iqbal, Med. Chem. 2019; 15: 298-310.
28. Sheldrick GM. SHELXS-97, Program for X-ray Crystal Structure Solution, Göttingen University, Göttingen, 1997.
29. Sheldrick GM. SHELXS-97, Program for X-ray Crystal Structure Refinement, Göttingen University, Göttingen, 1997.
30. Mustafa G, Khan IU, Ashraf M, Afzal I, Shahzad SA, Shafiq M. Bioorg. Med. Chem. 2012; 20: 2535–39.
31. Morris G, Huey R. J. Comput. Chem. 2009; 30: 2785–91.
32. BIOMAT Discovery Studio. Accelrys Software Inc., San Diego, 2019.
33. BIOVIA Discovery Studio Client v19.1.0.18287. Accelrys Discovery Studio. Accelrys Software Inc, San Diego, 2019.
34. Shaojie Wu, Wenhui Zhang, Le Qi, Yinghui Ren, Haixia Ma. J Mol. Struc. 2019; 5: 171-82.